SEGOVA
New Generation

Professor Ljubić's team has developed innovations in the ovaries and testes regeneration program called SEGOVA New Generation.

​

SEGOVA New Generation (NG) is the innovative, most complete available medical biological program for the rejuvenation and improvement of ovarian function. The new generation of the rejuvenation programme has evolved due to the implementation of the most recent findings and novel technologies in clinical practice.

​

SEGOVA NG implies a shortened procedure, which demands spending only one to two days in the hospital. This approach is possible due to the application of specific operative techniques during tissue retransplantation and the introduction of novel scaffolds (autologous activated bio-regenerative fibrin) which maintain retransplantation tissue and stem cells at the desired place within the ovarian or testicular tissue. SEGOVA NG also provides more precise visual control of tissue and stem cell retransplantation procedures.

​

Active principles in SEGOVA NG:

​

1. hcPRP - Activated autologous highly concentrated platelet growth factors (hcPRP)

2. BRF - Activated autologous bio-regenerative fibrin (BRF)

3. BM mSC - Mesenchymal bone marrow stem cells (bm mSC)

4. IVA - In Vitro Activated (IVA) ovarian tissue

5. Metabolic and physical optimisation - Patient's participation in metabolic optimization and specific training.

​

SEGOVA NG Procedure consists of the following:

​

1. Preparation:

• one or more days or weeks of preparation, including analyses of hormones, immunological status, infections, metabolism, vitamins, microelements and genetics.

 

2. Performing of SEGOVA NG Procedure:

• the one-day stay in the hospital, general anaesthesia

• blood is drawn from the patient to isolate and concentrate autologous PRP

• BRF (fully automatized closed system) and autologous thrombin. o Biopsy of the iliac bone and aspiration of the bone marrow

• separation and processing of mSC from the bone marrow aspirate concentrate (fully automatized closed system)

• minimally invasive laparoscopic surgery with tangential ovarian cortex excision.
  (+FSH/LH+GH+hCG)*

• administration of autologous activated haemostatics BRF instead of classical destructive surgical techniques

• IVA - micro-fragmentation of ovarian tissue submerged in mediums with autologous activated hcPRP

• careation of subcortical tunnels for the IVA ovarian cortical tissue and mSC retransplantation

• application of autologous activated BRF scaffold in the adequate subcortical tunnels

• application of the micro fragmented IVA ovarian cortical tissue with mSC and autologous activated hcPRP into the adequate subcortical spaces

• closure of the tunnels and re-creating the ovarian surface with the activated autologous BRF.

• control of haemostasis

• discharge from the hospital in 1 or 2 days.

 

3. The additional activities:

• the Nutritionist for Metabolic Optimisation and the physiotherapist gonadal HIIT program.

 

4. Reproductive follow-up:

• regular ultrasound and laboratory follow-up, with suggestions or implementation of advanced in vitro fertilisation techniques.

​

SEGOVA consists of several separate procedures integrated into a common project aimed to support, increase and/or create elements necessary for normal gonadal function. SEGOVA is a biological regenerative therapy which has been done in several hundreds of patients. Hormonal outcome - the success of SEGOVE in endocrine terms was in 85% of patients, in terms of improving hormone levels (AMH, FSH, LH, E2, Pg) up to 30%, which lasted over 2 years. From a reproductive point of view - the appearance of follicles had 61% of patients, eggs in 24%, and embryos in 17% of patients. Pregnancy was achieved in 15% of the monitored patients, and 10% had childbirth. *

​

* Not the final results, as 23 vitrified embryos (out of 71 obtained) have not been transferred.

​